// App-Quantinova.ai

5003 : Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Researchers

Presenter

  • Eric Jay Small

Principal Investigators

  • Jack Youngren

  • Matthew Rettig

  • Christopher P. Evans

  • Martin Edwin Gleave

  • Robert Baertsch

  • Josh Stuart

  • Robert Evan Reiter

  • Primo Lara

  • Kim N. Chi

  • George Thomas

  • Lawrence D. True

  • Li Zhang

  • Adam Foye

  • Joshi J. Alumkal

  • Charles J. Ryan

  • Tomasz M. Beer

  • Artem Sokolov

  • Rahul Raj Aggarwal

Medical Centers

  • University of Washington, Seattle, WA

  • UC Davis, Sacramento, CA

  • UC San Francisco, San Francisco, CA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • OHSU, Portland, ORInstitute of Pathology and Laboratory Medicine, UCLA, Los Angeles, CAUC Davis Comprehensive Cancer Center, Sacramento, CA

  • BC Cancer Agency, Vancouver, BC, Canada

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • UCLA, Los Angeles, CA

  • UC Santa Cruz, Santa Cruz, CA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved